Deep Braining...
TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

Lipocine Inc. (LPCN)
Lipocine Inc.
XNAS:LPCN
3.15
0.05%

Ask
$3.25 - 400.00
Bid
$3.11 - 86.00
Low
$3.14
High
$3.28
Open
$3.15
Prev Close
$3.15
52W High
5.5
52W Low
2.52
Volume
14662
Avg Vol (3m)
19605.9
Float
5394116.39
Chart
TendieTensor AI Analysis

Company
Asset Type: Common Stock
SIC Code: 2834
Sector: Health Technology
Industry: Pharmaceuticals: Major
Date Listed: 06/05/2012
Primary Exchange: XNAS

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Phone: 801 994 7383
Address: 675 Arapeen Drive, Suite 202
City: Salt Lake City
State: X1
Postal Code: 84108
TendieTensor AI Analyst Recommendation:
Fundamentals
Total Employees:
16
P/E (TTM)
-3.100000
P/B (TTM)
1.214970
Round Lot
100
Composit FIGI
BBG0029L1X69
Share Class FIGI
BBG0029L1Y76
Share Class Shares Outstanding
5.42M
Weighted Shares Outstanding
5.42M

Technicals
RSI (14)
MACD Line
MACD Signal
SMA 20
SMA 50
EMA 50
Trend
Short Interest
Days to Cover
Higher = harder to cover
Short Interest Δ
Prev: —
Short Volume Ratio (Today)
5D avg:
Squeeze Score (0–100)
Discussion
Login to participate in discussions.
Recent News
Related Stocks

Based on the portfolios of people who own LPCN. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.